David Tice is a prominent inventor based in Gaithersburg, MD (US), known for his significant contributions to the field of biotechnology. With a total of 9 patents to his name, Tice has made remarkable advancements in the development of therapeutic agents targeting various diseases, particularly cancers.

Latest Patents

Among his latest patents is the BCMA monoclonal antibody-drug conjugate. This invention focuses on an antibody-drug conjugate (ADC) that comprises a monoclonal antibody directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The patent also details compositions that include the ADC and methods for effectively killing multiple myeloma cells, including the stem cells that express BCMA. Another notable patent involves binding molecules specific for ASCT2. This disclosure presents ASCT2-binding molecules, such as anti-ASCT2 antibodies, which can be conjugated to cytotoxic drugs. These molecules are designed to bind specifically to cells expressing ASCT2 and can be utilized in diagnosing and treating diseases characterized by ASCT2 overexpression, including certain types of cancer.

Career Highlights

David Tice has worked with notable companies in the biotechnology sector, including MedImmune Limited. His work has significantly impacted the development of innovative therapies that address critical health challenges.

Collaborations

Throughout his career, Tice has collaborated with esteemed colleagues such as Partha S Chowdhury and Krista Lynne Kinneer. These collaborations have further enhanced his research and development efforts in the field.

Conclusion

David Tice's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and other medical applications.

This text is generated by artificial intelligence and may not be accurate.